Maze Therapeutics CEO Jason V. Coloma reports sale of common shares worth $921,153 - MAZE News | RalliesMaze Therapeutics CEO Jason V. Coloma reports sale of common shares worth $921,153
M
MAZE• CEO reports share sale
- Maze Therapeutics CEO Jason V. Coloma sold 34,501 common shares on Aug. 3, 2026 at about $26.71–$27.09 each.
- Sales were reported as indirect holdings through the Coloma 2021 Irrevocable Trust and the Coloma Family Trust.
- Post-transaction beneficial ownership: 20,744 shares in the Coloma 2021 Irrevocable Trust; 255,263 shares in the Coloma Family Trust.
ARLO
•
